Intravenous Iron Management for Pharmacists:
Safety, Efficacy, Dosing and Pharmacoeconomic Considerations
 
Medical Education Resources - Pharmacist CE Symposium, December, 2003
 
   THE TALKS
Access to this program is free but HDCN free zone registration is required.
Intravenous Iron Management: Safety, Efficacy, Dosing and Pharmacoeconomic Consideratons
Thomas Comstock, PharmD

   EDUCATIONAL OBJECTIVES

After participating in this activity, participants should be able to:
Assess the need for intravenous iron therapy to support erythropoiesis in selected patient populations
Identify and differentiate the IV iron products available in the US market today
Evaluate the published clinical data regarding the safety of IV iron infusion regimens
Identify the factors necessary to consider when establishing cost-effective guidelines for the use of IV iron therapy

   FACULTY
Thomas Comstock, PharmD
Associate Professor
Department of Pharmacy
Virginia Commonwealth University, School of Pharmacy
Richmond, VA

   CE INFORMATION
ACCREDITATION / DESIGNATION STATEMENT(S) :

HDCN is pleased to make available this web program devoted to the continuing education of pharmacists.

Pharmacy accreditation:
Medical Education Resources (MER)
is approved by the American Council of Pharmaceutical Education as a provider of continuing pharmaceutical education. MER designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the American Council on Pharmaceutical Education. Expires December 30, 2005. Universal Program Number: # 816-000-03-020-H04.

Intended Audience: Pharmacists. Note, this program is NOT intended for physicians or nurses, and no physician CME or nursing CE credit is available.

Needs Statement: Studies and clinical experience have demonstrated the important role for pharmacists in helping care for patients with anemia. Staying abreast of developments in anemia therapy is vital for the pharmacist to be able to optimize such care.

INSTRUCTIONS FOR PHARMACIST CE CREDIT :

To earn Pharmacist CE credit for viewing the lectures, please print and complete the CE Post test questions and return with the completed Evaluation Form to Medical Education Resources, Inc. via fax at (303) 798-5731 or mail at 1500 West Canal Court, Suite 500, Littleton, Colorado 80120-5617.

CE credit for this program has expired.  
FACULTY DISCLOSURE STATEMENTS :
All faculty participating in continuing medical education programs are expected to disclose to the program audience any real or apparent conflict of interest related to the subject under discussion. The faculty disclosure information is as follows:
Thomas Comstock, PharmD is a consultant and speakers' bureau participant for Watson Pharma, Inc.

DISCLOSURE OF UNLABELED USE (if applicable):
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by FDA. Medical Education Resources, Inc. or HDCN do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
All of the agents overviewed in this virtual symposium will be discussed in the context of uses for which they have not been approved by the FDA.
This educational activity is supported by an educational grant from Watson Pharmaceuticals Inc.

BACK TO
TOPIC INDEX :